What it's for (Indications)
- Valsartan + amlodipine + hydrochlorothiazide is indicated for the treatment of hypertension in patients whose blood pressure is not adequately controlled with dual therapy or as a substitute for the individually titrated components.
- This fixed-dose combination medication provides a synergistic approach to blood pressure management by targeting multiple pathophysiological pathways involved in hypertension, including the renin-angiotensin-aldosterone system, calcium channels, and fluid balance.
- It is typically utilized when a patient requires more aggressive blood pressure lowering or to simplify a complex medication regimen, thereby contributing to improved adherence and overall cardiovascular risk reduction.
- This combination is particularly beneficial for patients needing comprehensive control of their blood pressure.
Dosage Information
| Type | Guideline |
|---|---|
| Standard | The dosage of valsartan + amlodipine + hydrochlorothiazide must be individualized based on the patient's existing therapy, blood pressure response, and tolerability, with careful consideration of the dose of each component. It is typically administered orally once daily. For patients not adequately controlled on dual therapy (e.g., valsartan/amlodipine, valsartan/HCTZ, or amlodipine/HCTZ), a dose escalation of the combination product or its individual components might be necessary. Maximum recommended dosages for individual components should not be exceeded. Careful titration is essential, especially in patients with impaired renal or hepatic function, or those who are volume-depleted, to minimize the risk of hypotension and other adverse effects. Dosing should be reassessed after 2-4 weeks to achieve target blood pressure and optimize therapeutic benefit. |
Safety & Warnings
Common Side Effects
- Common side effects associated with valsartan + amlodipine + hydrochlorothiazide include dizziness, peripheral edema, headache, fatigue, and nasopharyngitis.
- Due to the hydrochlorothiazide component, electrolyte disturbances such as hypokalemia, hyponatremia, and hypomagnesemia can occur, as can hyperglycemia and hyperuricemia.
- Amlodipine, a calcium channel blocker, can cause flushing, palpitations, and gastrointestinal disturbances like nausea or abdominal pain.
- Valsartan, an ARB, may rarely lead to angioedema, a severe allergic reaction characterized by swelling of the face, lips, tongue, and/or pharynx.
- Orthostatic hypotension is also a potential concern, particularly in elderly patients or those who are volume-depleted.
- Patients should be advised to report any persistent, severe, or unusual adverse reactions to their healthcare provider for prompt evaluation and management.
Serious Warnings
- Black Box Warning: **WARNING: FETAL TOXICITY** * **Do not use in pregnancy.** Drugs that act directly on the renin-angiotensin system can cause injury and death to the developing fetus. When pregnancy is detected, discontinue valsartan + amlodipine + hydrochlorothiazide as soon as possible. There are no adequate and well-controlled studies of valsartan + amlodipine + hydrochlorothiazide in pregnant women. If pregnancy is detected, valsartan + amlodipine + hydrochlorothiazide should be discontinued as soon as possible. * The use of drugs that act on the renin-angiotensin system during the second and third trimesters of pregnancy has been associated with fetal injury, including oligohydramnios, which may result in fetal lung hypoplasia and skeletal deformations. Potential neonatal adverse effects include skull hypoplasia, anuria, hypotension, renal failure, and death. These adverse outcomes are typically associated with exposure during the later stages of pregnancy. Discontinue this medication if pregnancy is confirmed.
- Several significant warnings are associated with valsartan + amlodipine + hydrochlorothiazide, necessitating careful patient monitoring.
- Symptomatic hypotension may occur, especially in volume-depleted patients (e.
- g.
- , those on high-dose diuretics or with severe sodium restriction), requiring corrective measures before initiating therapy.
- Renal function should be routinely assessed, as the combination may cause decreases in renal function, particularly in patients with pre-existing renal impairment, severe congestive heart failure, or renovascular disease.
- While hydrochlorothiazide can cause hypokalemia, the valsartan component can lead to hyperkalemia, especially in patients with renal impairment or those taking potassium-sparing diuretics or potassium supplements, necessitating electrolyte monitoring.
- Angioedema, though rare, is a serious potential side effect of the ARB component.
- Patients with severe aortic stenosis may experience increased cardiac ischemia due to amlodipine's peripheral vasodilation.
- Systemic lupus erythematosus exacerbation has been reported with thiazide diuretics, and photosensitivity reactions may occur.
How it Works (Mechanism of Action)
This combination drug exerts its powerful antihypertensive effects through three distinct and complementary mechanisms. Valsartan, an angiotensin II receptor blocker (ARB), selectively blocks the binding of angiotensin II to the AT1 receptor in various tissues. This blockade leads to potent vasodilation, decreased aldosterone secretion (reducing sodium and water retention), and inhibition of cardiac and vascular remodeling, collectively lowering blood pressure. Amlodipine, a dihydropyridine calcium channel blocker, inhibits the transmembrane influx of calcium ions into vascular smooth muscle and cardiac muscle cells, predominantly causing peripheral arterial vasodilation and a significant reduction in peripheral vascular resistance without causing reflex tachycardia. Hydrochlorothiazide, a thiazide diuretic, increases the excretion of sodium, chloride, and water by inhibiting their reabsorption in the distal convoluted tubule of the nephron, thereby reducing plasma volume and indirectly lowering peripheral resistance. The synergistic action of these three agents contributes to comprehensive and effective blood pressure control.
Commercial Brands (Alternatives)
Exforge HCT 5/160/25mg
BrandNovartis
Valsartan+Amlodipine+Hydrochlorothiazide
Sofvasc-HTC 10mg/160mg/25mg
BrandWilson's
Valsartan+Amlodipine+Hydrochlorothiazide
Triforge
BrandHighnoon
Valsartan+Amlodipine+Hydrochlorothiazide (10mg)
Sofvasc-HCT 10mg/320mg/25mg
BrandWilson's
Valsartan+Amlodipine+Hydrochlorothiazide